Repository of Research and Investigative Information

Repository of Research and Investigative Information

Baqiyatallah University of Medical Sciences

Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins

(2020) Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins. Journal of Steroid Biochemistry and Molecular Biology. p. 11. ISSN 0960-0760

[img] Text
Breast cancer targeted therapeutic with double and triple fusion Immunotoxins.pdf

Download (6MB)

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

Target-specific transport of therapeutic agents holds promise to increase the efficacy of cancer treatment by decreasing injury to normal tissues and post treatment problems. HER2 is a tumor cell surface marker that is expressed in 25-30 of breast cancer patients. The significant role of HER2 in cancer development and its biological feature makes it a highly appealing goal for the therapeutic treatment of cancer targeted therapy using HER2 monoclonal antibody. This approach is currently used as a special treatment against breast cancer in some research. In the present study, HER2 monoclonal antibody (mAb), (Herceptin) fused to PE38 by recombinant DNA technology and a new recombinant IT was developed. The scFv(Herceptin)-PE-STXA and scFv(Herceptin)-PE fusions cloned in pET28a and recombinant protein expression was carried out and then the proteins were purified. MCF-7 and SKBR-3 cells were used as HER2-negative and HER2-positive breast cancer cells, respectively. The cytotoxicity of its evaluated using MIT assay. The cell ELISA was used to determine the binding ability of immunotoxins (ITs) to the cell receptor and internalization and apoptosis were also assessed. The results revealed that cell cytotoxicity occurred in SKBR-3 cells in a dose-dependent manner but not in MCF-7 cells. It is possible that this ITs can attach to HER2-positive breast cancer cells and then, internalize and eradicate cancer cells by apoptosis. Here, we concluded that the recombinant ITs have therapeutic potential against HER2-positive breast cancer.

Item Type: Article
Keywords: PE38 Herceptin HER2 Breast cancer Apoptosis antibody-based immunotoxins shiga toxin antitumor-activity exotoxin-a in-vitro protein tgf-alpha-l3-seb internalization cytotoxicity optimization Biochemistry & Molecular Biology Endocrinology & Metabolism
Page Range: p. 11
Journal or Publication Title: Journal of Steroid Biochemistry and Molecular Biology
Journal Index: ISI
Volume: 200
Identification Number: https://doi.org/10.1016/j.jsbmb.2020.105651
ISSN: 0960-0760
Depositing User: مهندس مهدی شریفی
URI: http://eprints.bmsu.ac.ir/id/eprint/8791

Actions (login required)

View Item View Item